Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line

Sakurai, Masatoshi; Okamoto, Shinichiro; Matsumura, Itaru; Murakami, Satona; Takizawa, Makiko; Waki, Masato; Hirano, Daiki; Watanabe-Nakaseko, Reiko; Kobayashi, Naoki; Iino, Masaki; Matsui, Hideki; Ishikawa, Yuichi; Takahashi, Naoto; Kawaguchi, Tatsuya; Suzuki, Ritsuro; Yamamoto, Kazuhito; Kizaki, Masahiro; Ohnishi, Kazunori; Naoe, Tomoki; Akashi, Koichi; investigators, New Target

doi:10.1007/s12185-020-02843-8

Cited by 5 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunitinib is the second-line TKI for the management of GISTs if disease progression or intolerance to first-line imatinib treatment occurs. [31] According to the current guidance, 10% to 14% of GIST patients show primary resistance to imatinib, and over 50% develop secondary (acquired) resistance within approximately 2 years of IM treatment. [27,28] Acquired resistance is usually related to the emergence of secondary mutations in KIT or PDGFRA .…”

Section: Use Of Second- and Third-line Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

The current state of chemotherapy for the treatment of gastrointestinal stromal tumors with different genotypes: a narrative review

Xiao

et al. 2021

J Bio-X Res

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the digestive system and are not sensitive to traditional chemotherapy. Therefore, historically, surgical resection was the only effective therapy. However, the emergence of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of GISTs, because they target c-Kit and PDGF receptor-a (PDGFRA), which are important in GIST development and progression. As research into c-Kit and PDGFRA continues, an increasing number of different TKIs are being used in the clinical setting. This review aims to discuss the current state of chemotherapy for the treatment of GISTs with different genotypes.

show abstract

Section: Use Of Second- and Third-line Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

The current state of chemotherapy for the treatment of gastrointestinal stromal tumors with different genotypes: a narrative review

Xiao

et al. 2021

J Bio-X Res

View full text Add to dashboard Cite

show abstract

“… 6 , 9 , 10 , 11 Of these, imatinib, nilotinib, dasatinib, and recently bosutinib are approved in Japan for both newly diagnosed patients and those resistant and/or intolerant to prior TKI therapy. 6 , 9 , 10 , 11 Current practice guidelines in Japan recommend imatinib, nilotinib, and dasatinib for newly diagnosed patients with CML in chronic phase (CML‐CP). 6 For patients resistant or intolerant to first‐line TKIs, Japanese practice guidelines recommend switching to a different TKI with a non‐overlapping resistance profile to the first‐line agent, including any second‐generation TKI not already used, bosutinib, or ponatinib.…”

Section: Introductionmentioning

confidence: 99%

“… 6 Previous studies conducted in Japanese patients with CML‐CP who are treatment‐naive or resistant and/or intolerant to a first‐line TKI demonstrated reliable outcomes with second‐generation TKIs and the third‐generation TKI ponatinib. 9 , 11 , 12 , 13 , 14 , 15 However, with each additional line of treatment using currently available TKIs, the incidence of treatment failure and disease progression increases. 10 , 16 , 17 Thus, there is a need for effective therapy options for patients with CML who have failed previous treatment with currently approved TKIs.…”

Section: Introductionmentioning

confidence: 99%

“…8 TKIs currently available in Japan include the firstgeneration TKI imatinib, the second-generation TKIs nilotinib, dasatinib, and bosutinib, and the third-generation TKI ponatinib. 6,[9][10][11] Of these, imatinib, nilotinib, dasatinib, and recently bosutinib are approved in Japan for both newly diagnosed patients and those resistant and/or intolerant to prior TKI therapy. 6,[9][10][11] Current practice guidelines in Japan recommend imatinib, nilotinib, and dasatinib for newly diagnosed patients with CML in chronic phase (CML-CP).…”

Section: Introductionmentioning

confidence: 99%

“…For patients resistant or intolerant to first‐line TKIs, Japanese practice guidelines recommend switching to a different TKI with a non‐overlapping resistance profile to the first‐line agent, including any second‐generation TKI not already used, bosutinib, or ponatinib 6 . Previous studies conducted in Japanese patients with CML‐CP who are treatment‐naive or resistant and/or intolerant to a first‐line TKI demonstrated reliable outcomes with second‐generation TKIs and the third‐generation TKI ponatinib 9,11–15 . However, with each additional line of treatment using currently available TKIs, the incidence of treatment failure and disease progression increases 10,16,17 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Asciminib, a first‐in‐class, allosteric inhibitor of BCR‐ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3, open‐label ASCEMBL study in patients with CML in chronic phase (CML‐CP) pretreated with ≥2 tyrosine kinase inhibitors (TKIs) (NCT03106779), asciminib (40 mg twice‐daily) demonstrated significant superiority over the ATP‐competitive TKI bosutinib (500 mg once daily) for the primary endpoint of major molecular response (MMR; BCR::ABL1 transcript levels on the international scale [ BCR::ABL1 IS ] ≤0.1%) at week 24. Here, we report results from a descriptive subgroup analysis of Japanese patients enrolled in ASCEMBL study (data cut‐off: May 25, 2020). Overall, 16 Japanese patients were randomized (asciminib, n = 13; bosutinib, n = 3). At week 24, the MMR rate with asciminib was 30.8% (4/13; 95% confidence interval [CI], 9.09–61.43). BCR::ABL1 IS ≤1% and complete cytogenic response (CCyR) at week 24 were 61.5% (8/13 patients) and 50.0% (4/8 patients), respectively. In the bosutinib group, no patient achieved MMR, CCyR, or BCR::ABL1 IS ≤1%, but results were limited by the low number of patients. The safety profile of asciminib was comparable to that previously observed in the overall study population. Findings from this Japanese subgroup analysis of the ASCEMBL study support the use of asciminib for the treatment of Japanese patients with CML‐CP previously treated with ≥2 TKIs. ClinicalTrials.gov Identifier: NCT03106779.

show abstract

Real-world Management of CML: Outcomes and Treatment Patterns

Held

Atallah

2023

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line

Cited by 5 publications

References 30 publications

The current state of chemotherapy for the treatment of gastrointestinal stromal tumors with different genotypes: a narrative review

The current state of chemotherapy for the treatment of gastrointestinal stromal tumors with different genotypes: a narrative review

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

Real-world Management of CML: Outcomes and Treatment Patterns

Contact Info

Product

Resources

About